- Company
- Perjeta and Herceptin combination drug, Phesgo
- by Eo, Yun-Ho Aug 30, 2023 05:31am
- Phesgo, a subcutaneous injection-type combination of Perjeta and Herceptin, challenges insurance coverage registration. As a result of the coverage, Phesgo of Roche Korea is presented to the Cancer Disease Review Committee of the HIRA today (30th). This is the first case of an improved anti-cancer biobetter. Biobetter refers to drugs reco
- Company
- Keytruda posts sales of KRW 183.8 bil in 1H...unrivaled lead
- by Chon, Seung-Hyun Aug 29, 2023 05:28am
- The immuno-oncology drug Keytruda’s sales have been skyrocketing in the domestic drug market. In the first half of the year alone, the drug posted sales of over KRW 200 billion and secured its unrivaled lead in the market. The drug’s sales have been rising more steeply after the drug’s reimbursement was extended as first-line therapy last yea
- Company
- The synergy between technology and sales force
- by Chon, Seung-Hyun Aug 29, 2023 05:28am
- Domestically developed biosimilar products are prominent in the large anticancer drug Asastin market. Samsungbioepis' Onbevzi exceeded 10 billion won in quarterly sales in the first two years of its release, showing a 35% share. It is said that Boryung, which was the first biosimilar to enter the market and has differentiated strengths in antica
- Company
- Verquvo busy securing prescriptions in KOR with reimb
- by Eo, Yun-Ho Aug 29, 2023 05:28am
- The new heart failure drug ‘Verquvo’ is busy securing prescriptions in Korea with its reimbursement listing. According to industry sources, Bayer Korea’s soluble Guanylate Cyclase (sGC) stimulator Verquvo (Vericiguat)’ passed the drug committees of Korea Anam Hospital, Chung-Ang University Gwangmyeong Hospital, Seoul National Universi
- Company
- Price negotiation period for Spinraza and Evrysdi extended
- by Eo, Yun-Ho Aug 28, 2023 05:21am
- The companies of the spinal muscular atrophy (SMA) treatments ‘Spinraza’ and ‘Evrysdi’ failed to conclude drug pricing negotiations for their drugs within the deadline and began extended negotiations. As a result, Spinraza reimbursement extension and Evrysdi’s new listing will only be possible in October at the earliest. Accordi
- Company
- Trulicity's share reaches 99.8%
- by Kim, Jin-Gu Aug 28, 2023 05:21am
- Trulicity, a GLP-1 analog class diabetes treatment, once again set the record for highest sales. However, it is unclear whether this upward trend will continue in the second half. This is because it is said that some disruptions have occurred in domestic supply due to a shortage of global distribution supplies. Ozempic and Rybelsus, which ar
- Company
- Discussion on expanding coverage for Leclaza begins
- by Eo, Yun-Ho Aug 28, 2023 05:21am
- Attention is focused on expanding insurance coverage for the first-line treatment of the anticancer drug Leclaza. According to related industries, Yuhan Corporation's 3rd generation EGFR TKI Leclaza will be scheduled for the HIRA on the 30th. The specific indication is 'primary treatment for EGFR active non-small cell lung cancer'. Leclaza o
- Company
- New drug Shingrix leads shingles vaccine mkt
- by Chon, Seung-Hyun Aug 28, 2023 05:21am
- GlaxoSmithKline's shingles vaccine 'Shingrix' took the lead in Korea’s market just 7 months after its release. With its powerful shingles prevention effect, its sales surpassed that of its competitors. SkYZoster, a homegrown vaccine, had taken the lead in the market for the first time at the end of last year but was overtaken by Shingrix in jus
- Company
- Hanmi Pharm starts P1T on its next-gen immuno-oncology drug
- by Chon, Seung-Hyun Aug 25, 2023 06:06am
- On the 22nd, Hanmi Pharm announced that it has recently received approval to initiate a domestic Phase I trial for its next-generation immuno-oncology drug ‘‘BH3120(PD-L1/4-1BB BsAb)’ from the Ministry of Food and Drug Safety. In May, the company had previously received approval from the US FDA for the same drug candidate after submitting an
- Company
- Company Roche and Drug Keytruda will lead industry in 5 yrs
- by Kim, Jin-Gu Aug 25, 2023 06:06am
- A projection has been made that Roche will become the top global-grossing pharmaceutical company 5 years from now in 2028. Evaluate, the global pharmaceutical market analysis institution that released such projections, also predicted that Keytruda would take over Humira’s throne and become the No. 1 grossing drug among pharmaceuticals. On th
